Table 3. Results of non-invasive fibrosis assessment.
| All patients n=392 | Test cohort n=307 | Validation cohort n=85 | P-value | ||
|---|---|---|---|---|---|
| Liver disease etiology | |||||
| sAxl level (ng/ml); median (IQR) | Liver disease, n=361 | 45.7 (37.2;60.8) | 44.0 (36.1;59.1) | 53.0 (42.3;70.1) | 0.002 |
| NAFLD | 41.2 (33.8;52.8) | 40.7 (33.0;50.8) | 43.7 (36.4;57.5) | 0.076 | |
| Viral hepatitis | 56.6 (43.3;71.7) | 56.5 (43.0;77.3) | 57.3 (43.4;70.8) | 0.945 | |
| AIH/CLD/Overlap | 45.6 (37.6;70.2) | 43.7 (36.2;60.3) | 77.4 (51.9;83.0) | 0.001 | |
| DILI | 47.9 (34.5;75.4) | 62.2 (36.3;103.0) | n.d. | n.d. | |
| ALD | 63.5 (47.4;92.1) | 63.5 (47.4;92.1) | n.d. | n.d. | |
| Cryptogenic | 51.2 (38.7;67.2) | 50.1 (38.1;62.7) | n.d. | n.d. | |
| Healthy controls, n=31 | 40.2 (34.2;48.0) | 40.2 (34.2;48.0) | n.d. | n.d. | |
| sAxl/albumin; median (IQR) | Liver disease, n=361 | (0.82;1.38) | 1.00 (0.80;1.39) | 1.21 (0.89;1.56) | 0.004 |
| NAFLD | 0.92 (0.75;1.14) | 0.92 (0.75;1.13) | 0.93 (0.80;1.32) | 0.322 | |
| Viral hepatitis | 1.29 (0.97;1.69) | 1.32 (0.96;1.94) | 1.28 (0.98;1.58) | 0.537 | |
| AIH/CLD/Overlap | 1.07 (0.86;1.56) | 0.99 (0.84;1.40) | 1.94 (1.20;2.46) | 0.002 | |
| DILI | 1.16 (0.78;1.78) | 1.50 (0.86;2.63) | n.d. | ||
| ALD | 1.72 (1.07;2.59) | 1.72 (1.07;2.59) | n.d. | ||
| Cryptogenic | 1.11 (0.86;1.70) | 1.08 (0.85;1.68) | n.d. | ||
| Healthy controls, n=31 | 0.85 (0.78;1.04) | 0.85 (0.78;1.04) | n.d. | ||
| ELFTM test (ng/ml); median (IQR) | Liver disease, n=305 | 9.0 (8.3;10.1) | 9.2 (8.4;10.5) | 8.7 (8.1;9.5) | 0.012 |
| NAFLD, n=162 | 8.7 (8.1;9.5) | 8.8 (8.2;9.7) | 8.3 (7.9;9.0) | 0.009 | |
| Viral hepatitis, n=66 | 9.3 (8.6;10.3) | 9.9 (8.8;11.0) | 9.0 (8.6;9.8) | 0.033 | |
| AIH/CLD/Overlap, n=62 | 9.4 (8.3;10.8) | 9.4 (8.3;10.7) | 9.0 (8.3;11.6) | 0.781 | |
| DILI | n.d. | n.d. | n.d. | n.d. | |
| ALD, n=13 | 11.5 (10.1;12.4) | 11.5 (10.1;12.4) | n.d. | n.d. | |
| Cryptogenic | n.d. | n.d. | n.d. | n.d. | |
| Healthy controls, n=27 | 8.7 (8.0;9.3) | 8.7 (8.0;9.3) | n.d. | n.d. | |
| Fibroscan (kPa); median (IQR) | Liver disease, n=131 | 7.9 (5.8;11.8) | 8.0 (6.0;11.6) | 7.8 (5.4;11.8) | 0.715 |
| NAFLD, n=75 | 8.1 (6.0;10.6) | 8.4 (6.2;11.4) | 7.6 (5.8;10.5) | 0.841 | |
| Viral hepatitis, n=33 | 8.8 (4.9;12.6) | n.d. | 8.8 (4.9;12.5) | n.d. | |
| AIH/CLD/Overlap, n=18 | 7.2 (5.9;10.1) | 6.4 (5.8;10.4) | 7.8 (6.9;10.0) | 0.328 | |
| DILI | n.d. | n.d. | n.d. | n.d. | |
| ALD | n.d. | n.d. | n.d. | n.d. | |
| Cryptogenic | n.d. | n.d. | n.d. | n.d. | |
| Healthy controls, n=0 | n.d. | n.d. | n.d. | n.d. |
Results of non-invasive fibrosis markers were compared by Mann Whitney U – test. n.d., not determined